Product Description
Perindopril is used alone or in combination with other medications to treat high blood pressure. Perindopril is in a class of medications called angiotensin-converting enzyme (ACE) inhibitors. It makes blood flow more smoothly by preventing the production of certain natural chemicals that tighten the blood vessels. (Sourced from: https://medlineplus.gov/druginfo/meds/a602017.html)
Mechanisms of Action: ACE Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Myocardial Infarction | Hypertension | Stroke | Acute Myeloid Leukemia
Known Adverse Events: Dizziness | Headache | Edema
Company: Servier
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Belgium, Canada, China, Colombia, Croatia, Germany, Hungary, India, Ireland, Japan, Jordan, Nepal, Netherlands, New Zealand, Pakistan, Portugal, Romania, Russia, Saudi Arabia, Spain, United Kingdom, United States
Active Clinical Trial Count:
Highest Development Phases
Phase 3: COVID-19|Hypertension|Influenza, Human|Pneumonia
Phase 2: Cardiomyopathy, Hypertrophic
Phase 1: Acute Myeloid Leukemia|Acute Respiratory Distress Syndrome|Healthy Volunteers|Osteoporosis, Postmenopausal
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| REMAP-CAP | P3 |
Recruiting |
Pneumonia|COVID-19|Influenza, Human |
2026-02-01 |
|
| 2020-004891-16 | P3 |
Active, not recruiting |
Hypertension |
2024-12-29 |
|
| BE-PER01-23 | P1 |
Recruiting |
Acute Respiratory Distress Syndrome |
2024-03-06 |
28% |
| PIA_PT_01 | P1 |
Recruiting |
Acute Respiratory Distress Syndrome|Acute Myeloid Leukemia |
2023-08-17 |
53% |